GLP-1 drugs double the short-term risk of small intestinal bacterial overgrowth in diabetics | Research

The takeaway

In 432,346 propensity-matched T2DM patients, GLP-1RA/GIP therapy was associated with 2.14x higher short-term SIBO risk (HR 2.14, p=0.049) versus other diabetes drugs, with a sustained trend in long-term analysis (HR 2.02, NS but Kaplan-Meier p=0.017).

2.14x SIBO risk
GLP-1/GIP drugs doubled the short-term risk of small intestinal bacterial overgrowth in 432,346 matched diabetic patients, likely from impaired gut motility

What the researchers found

Short-term SIBO: HR 2.14 (1.13-4.07, p=0.049). Incidence: 0.177 vs 0.083 per 1,000 patient-years. Long-term: HR 2.02 (0.98-4.12, NS), but KM divergence p=0.017. 216,173 per cohort. TriNetX database.

Why it matters

SIBO causes bloating, malabsorption, and nutritional deficiencies—symptoms that overlap with GLP-1 drug side effects. Clinicians need to consider SIBO as a possible diagnosis in GLP-1 users with persistent GI symptoms.

How the study worked

Retrospective cohort from TriNetX global database. Adult T2DM patients on GLP-1RA/GIP vs other second-line agents. 1:1 propensity matching (216,173 per group). Short and long-term SIBO analysis.

What this study cannot tell us

Retrospective. SIBO diagnosis depends on breath testing availability. Very low absolute incidence. Cannot determine which GLP-1 drugs drive the risk. Excluded gastroparesis patients may have biased results.

How to read the evidence

Large propensity-matched cohort from global database. Significant short-term finding with sustained long-term trend.

When this study was published

Published in 2025; data 2006-2024.

The bigger picture

GLP-1 drugs' motility-slowing effects have consequences beyond nausea. SIBO is a clinically important but potentially underdiagnosed complication that may explain some patients' persistent GI symptoms.

Questions still open

Should GLP-1 patients with persistent GI symptoms be tested for SIBO?
Does SIBO risk vary between different GLP-1 drugs?
Would prokinetic agents reduce SIBO risk during GLP-1 therapy?

Common questions

Can GLP-1 drugs cause gut bacterial overgrowth?

This large study found GLP-1 drugs double the risk of SIBO—a condition where bacteria overgrow in the small intestine due to slowed gut movement. While the absolute risk is low (about 0.18 per 1,000 patient-years), it may explain persistent bloating, gas, or diarrhea in some GLP-1 users.

What should I do if I have ongoing stomach problems on GLP-1 drugs?

If you have persistent bloating, diarrhea, or nutritional deficiency symptoms that do not improve with time or dose adjustment, ask your doctor about testing for SIBO. A simple breath test can diagnose it, and treatment with specific antibiotics is usually effective.

Read the original research

Diagnostic Evaluation of an Increased Risk of Developing Small Intestinal Bacterial Overgrowth Associated with Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Dual GLP-1/GIP Receptor Agonists: A Global Retrospective Multicenter Cohort Analysis.

Diagnostics (Basel, Switzerland), 15(17)

View on PubMed ↗Publisher’s paper ↗

Citation

Sun, Yan; Veccia, Donovan; Liu, Benjamin Douglas Xun; Tse, William; Fass, Ronnie; Song, Gengqing. (2025). Diagnostic Evaluation of an Increased Risk of Developing Small Intestinal Bacterial Overgrowth Associated with Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Dual GLP-1/GIP Receptor Agonists: A Global Retrospective Multicenter Cohort Analysis.. Diagnostics (Basel, Switzerland), 15(17). https://doi.org/10.3390/diagnostics15172264